A Breast Cancer Drug Approved on July 14 Was Added to National Treatment Guidelines Sixteen Days Later

Gedatolisib was placed in the NCCN breast cancer guidelines as a preferred Category 1 option 16 days after FDA approval. What does that rating mean?

Have A Referral?